Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Oct 27, 2026; 18(10): 123267
Published online Oct 27, 2026. doi: 10.4254/wjh.123267
Published online Oct 27, 2026. doi: 10.4254/wjh.123267
Proactive antithyroid therapy improves survival in hyperthyroidism-induced liver injury: A real-world cohort study
Wen Yu, Zhong-Shang Dai, Yu-Hong Li, Mao-Ping Li, Jie Li, Ke-Xin Jiao, Jing Ma, Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
Yi Li, Institute of Hepatology, Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
Co-first authors: Wen Yu and Zhong-Shang Dai.
Author contributions: Yu W and Dai ZS wrote the main manuscript text and prepared figures and tables as co-first authors; Yu W, Li YH, Li MP and Li J are responsible for data collecting; Dai ZS, Jiao KX and Ma J analyzed all data; Li Y designed the study; all authors reviewed the manuscript.
AI contribution statement: We did not use ChatGPT, Grammarly, DeepL, or any other AI tool. None of the main text of answering-reviewers was AI-generated. No AI tool was used for language polishing, translation, data analysis, or writing assistance of the answering-reviewers. No AI tool participated in the design of the study or interpretation of its results. No Figures in the manuscript were generated by AI.
Supported by National Natural Science Foundation of China, No. 82370640.
Institutional review board statement: The research was approved by the Ethics Committee of the Second Xiangya Hospital, Central South University, No. LYEC2026-0107.
Clinical trial registration statement: This study does not involve a clinical trial; therefore, clinical trial registration is not required.
Informed consent statement: All participants provided informed consent.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: All data of this study are available from the corresponding author for reasonable request.
Corresponding author: Yi Li, MD, Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, No. 139 Renmin Middle Road, Changsha 410011, Hunan Province, China. liyi731128@csu.edu.cn
Received: May 13, 2026
Revised: July 2, 2026
Accepted: September 15, 2026
Published online: October 27, 2026
Processing time: 161 Days and 12.1 Hours
Revised: July 2, 2026
Accepted: September 15, 2026
Published online: October 27, 2026
Processing time: 161 Days and 12.1 Hours
Core Tip
Core Tip: Hyperthyroidism-related liver injury is common in clinical practice, yet evidence for initial antithyroid drug (ATD) use in ATD-naive patients is insufficient. This study demonstrates that early ATD treatment is safe and effective, can improve thyroid function and liver injury recovery, and may reduce long-term adverse outcomes, providing a reference for clinical decision-making.